Atox Bio was granted orphan drug designation by the FDA for its drug candidate AB103 for the treatment of necrotizing soft tissue infections (NSTI). AB103 is a rationally designed short peptide acting as a CD28 modulator regulating the host’s inflammatory response. AB103 has successfully completed a Phase 1 study and will shortly go into a Phase 2 proof of concept study evaluating its clinical benefit when administered in addition to standard of care in up to 56 NSTI patients at 7 surgical trauma centers.

For more information visit www.atoxbio.com.